search
Back to results

Evaluation of Integrated Cardiac Imaging in Ischemic Heart Disease (EVINCI)

Primary Purpose

Ischemic Heart Disease

Status
Completed
Phase
Phase 4
Locations
International
Study Type
Interventional
Intervention
Non invasive cardiac imaging
Sponsored by
Fondazione C.N.R./Regione Toscana "G. Monasterio", Pisa, Italy
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Ischemic Heart Disease focused on measuring IHD, CAD, Non invasive imaging, SPECT, PET, CMR, Echocardiography

Eligibility Criteria

30 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients with intermediate (>20%, <90%) risk of IHD based on age,gender,symptoms and exercise stress test results

Exclusion Criteria:

  • Age < 30 Yrs or > 75 yrs
  • Pregnancy (suspected or ascertained)
  • LV Dysfunction (LVEF < 35% by Echo or other method)
  • Low (< =20%) or high (>=90%) probability of CAD
  • Acute Coronary Syndrome
  • Prolonged (> 20 minutes) chest pain
  • De novo or accelerated angina
  • Hemodynamic or electrical instability
  • Recent ST-T segment or T wave changes of ischemic nature
  • Acute myocardial infarction with or without ST segment elevation
  • Elevated serum cardiac markers of necrosis
  • Known diagnosis of CAD
  • Previously known myocardial infarction
  • Previous PCI
  • Previous CABG
  • Persistent atrial fibrillation or advanced AV Block
  • Asthma or chronic treatment with aminophylline
  • Recent (<6 months) cerebral ischemic attack
  • Known significant carotid stenosis or vascular aneurisms
  • Asthma or chronic treatment with aminophylline
  • Active cancer
  • Severe hypertension. Patients cannot withdraw therapy for 12 hours.
  • Congenital heart disease
  • Significant valvular disease
  • Cardiomyopathy (e.g. DCM, HCM, ARVC, Amyloidosis)
  • Inability to provide an informed consent

Sites / Locations

  • U.Turku
  • APHP
  • KAE Goeppingen
  • TUM
  • Ospedale Versilia
  • UniGE
  • UniNA
  • CNR
  • FGM
  • LUMC
  • NIC
  • Huvhebron
  • SERMAS
  • UZH
  • QUEEN MARY Hospital London
  • RBHT

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Non invasive cardiac imaging

Arm Description

Intervention: Non invasive cardiac imaging. 'Anatomical' information provided by CTCA is obtained in every patient together with the 'functional' information provided by stress radionuclide cardiac imaging (SPECT or PET), to assess myocardial perfusion, and/or by stress MRI or ECHO imaging to assess myocardial contraction.

Outcomes

Primary Outcome Measures

Diagnosis of IHD at Invasive Coronary Angiography and FFR Measurement
The outcome measure is the number of participants who received the diagnosis of IHD at invasive coronary angiography coupled with FFR measurements (in case of intermediate coronary lesions).

Secondary Outcome Measures

Cost-benefit and Cost-effectiveness Analysis
Different non invasive imaging modalities are compared in terms of a cost-effectiveness analysis where costs include direct and indirect costs incurred as a consequence of the use of each modality or combination of modalities and effectiveness is the diagnostic accuracy with invasive diagnosis of IHD as end-point.

Full Information

First Posted
September 16, 2009
Last Updated
June 19, 2014
Sponsor
Fondazione C.N.R./Regione Toscana "G. Monasterio", Pisa, Italy
Collaborators
European Commission
search

1. Study Identification

Unique Protocol Identification Number
NCT00979199
Brief Title
Evaluation of Integrated Cardiac Imaging in Ischemic Heart Disease
Acronym
EVINCI
Official Title
Evaluation of Integrated Cardiac Imaging for the Detection and Characterization of Ischemic Heart Disease
Study Type
Interventional

2. Study Status

Record Verification Date
June 2014
Overall Recruitment Status
Completed
Study Start Date
February 2009 (undefined)
Primary Completion Date
July 2010 (Actual)
Study Completion Date
June 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Fondazione C.N.R./Regione Toscana "G. Monasterio", Pisa, Italy
Collaborators
European Commission

4. Oversight

5. Study Description

Brief Summary
Main purpose of the study: To comparatively assess the diagnostic performance of non invasive anatomical and functional imaging modalities to detect significant obstructive coronary artery disease as demonstrated at invasive coronary angiography and functional evaluation of coronary lesions (fractional flow reserve).
Detailed Description
Objectives of the study To test the accuracy of anatomical and functional non-invasive cardiac imaging in the diagnosis of IHD. To this purpose the "anatomical" information provided by CTA is obtained in every patient together with the "functional" information provided by stress radionuclide cardiac imaging (SPECT or PET), to assess myocardial perfusion, and/or by stress MRI or ECHO imaging to assess myocardial contraction. Non-invasive results are tested against invasive reference standards. The latter consists of invasive coronary angiography integrated by invasive measurement of fractional flow reserve (to assess the hemodynamic relevance of intermediate coronary stenoses). To test the accuracy of integrated models, including clinical variables, risk factors and circulating biomarkers, to predict significant obstructive coronary artery disease in patients with chronic angina-like symptoms. To correlate biohumoral profiles with the coronary anatomical-functional phenotype as obtained by non invasive imaging in the same patients. To reach these goals the clinical characterization of patients (collected before non-invasive imaging) and the laboratory characterization (that includes novel biomarkers of cardiovascular risk) are compared with patient characterization derived from non invasive "anatomic-functional" imaging and with invasive diagnosis of significantly obstructive coronary disease. To develop an advanced clinical and imaging reporting tool in cardiology. An informatics platform is developed to synthetically and clearly present the integrated clinical and imaging diagnostic profile of individual patients. A multimodal imaging reporting tool is developed including tools for "image fusion" of different imaging modalities (CT, SPECT, PET, MRI). To define the most cost-effective work-up for the diagnosis and characterization of IHD. To this purpose the costs and the procedural risks (including radiation exposure) of non-invasive and invasive diagnostic procedures are prospectively collected. Cost-benefit and cost-effectiveness analyses is conducted alongside the EVINCI-study clinical trial.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ischemic Heart Disease
Keywords
IHD, CAD, Non invasive imaging, SPECT, PET, CMR, Echocardiography

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
697 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Non invasive cardiac imaging
Arm Type
Other
Arm Description
Intervention: Non invasive cardiac imaging. 'Anatomical' information provided by CTCA is obtained in every patient together with the 'functional' information provided by stress radionuclide cardiac imaging (SPECT or PET), to assess myocardial perfusion, and/or by stress MRI or ECHO imaging to assess myocardial contraction.
Intervention Type
Other
Intervention Name(s)
Non invasive cardiac imaging
Intervention Description
Non invasive cardiac imaging consists of CTCA combined with one Stress Imaging Test
Primary Outcome Measure Information:
Title
Diagnosis of IHD at Invasive Coronary Angiography and FFR Measurement
Description
The outcome measure is the number of participants who received the diagnosis of IHD at invasive coronary angiography coupled with FFR measurements (in case of intermediate coronary lesions).
Time Frame
3 months from enrollment
Secondary Outcome Measure Information:
Title
Cost-benefit and Cost-effectiveness Analysis
Description
Different non invasive imaging modalities are compared in terms of a cost-effectiveness analysis where costs include direct and indirect costs incurred as a consequence of the use of each modality or combination of modalities and effectiveness is the diagnostic accuracy with invasive diagnosis of IHD as end-point.
Time Frame
3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with intermediate (>20%, <90%) risk of IHD based on age,gender,symptoms and exercise stress test results Exclusion Criteria: Age < 30 Yrs or > 75 yrs Pregnancy (suspected or ascertained) LV Dysfunction (LVEF < 35% by Echo or other method) Low (< =20%) or high (>=90%) probability of CAD Acute Coronary Syndrome Prolonged (> 20 minutes) chest pain De novo or accelerated angina Hemodynamic or electrical instability Recent ST-T segment or T wave changes of ischemic nature Acute myocardial infarction with or without ST segment elevation Elevated serum cardiac markers of necrosis Known diagnosis of CAD Previously known myocardial infarction Previous PCI Previous CABG Persistent atrial fibrillation or advanced AV Block Asthma or chronic treatment with aminophylline Recent (<6 months) cerebral ischemic attack Known significant carotid stenosis or vascular aneurisms Asthma or chronic treatment with aminophylline Active cancer Severe hypertension. Patients cannot withdraw therapy for 12 hours. Congenital heart disease Significant valvular disease Cardiomyopathy (e.g. DCM, HCM, ARVC, Amyloidosis) Inability to provide an informed consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Danilo Neglia, MD, PhD
Organizational Affiliation
Fondazione Toscana G. Monasterio, Pisa, Italy
Official's Role
Principal Investigator
Facility Information:
Facility Name
U.Turku
City
Turku
Country
Finland
Facility Name
APHP
City
Paris
Country
France
Facility Name
KAE Goeppingen
City
Goeppingen
Country
Germany
Facility Name
TUM
City
Munich
Country
Germany
Facility Name
Ospedale Versilia
City
Viareggio
State/Province
Lucca
ZIP/Postal Code
55100
Country
Italy
Facility Name
UniGE
City
Genova
Country
Italy
Facility Name
UniNA
City
Naples
Country
Italy
Facility Name
CNR
City
Pisa
Country
Italy
Facility Name
FGM
City
Pisa
Country
Italy
Facility Name
LUMC
City
Leiden
Country
Netherlands
Facility Name
NIC
City
Warsaw
Country
Poland
Facility Name
Huvhebron
City
Barcelona
Country
Spain
Facility Name
SERMAS
City
Madrid
Country
Spain
Facility Name
UZH
City
Zurich
Country
Switzerland
Facility Name
QUEEN MARY Hospital London
City
London
Country
United Kingdom
Facility Name
RBHT
City
London
Country
United Kingdom

12. IPD Sharing Statement

Citations:
PubMed Identifier
34671067
Citation
Caselli C, De Caterina R, Smit JM, Campolo J, El Mahdiui M, Ragusa R, Clemente A, Sampietro T, Clerico A, Liga R, Pelosi G, Rocchiccioli S, Parodi O, Scholte A, Knuuti J, Neglia D; EVINCI and SMARTool. Triglycerides and low HDL cholesterol predict coronary heart disease risk in patients with stable angina. Sci Rep. 2021 Oct 20;11(1):20714. doi: 10.1038/s41598-021-00020-3.
Results Reference
derived
PubMed Identifier
31672148
Citation
Caselli C, Del Turco S, Ragusa R, Lorenzoni V, De Graaf M, Basta G, Scholte A, De Caterina R, Neglia D. Association of PCSK9 plasma levels with metabolic patterns and coronary atherosclerosis in patients with stable angina. Cardiovasc Diabetol. 2019 Oct 31;18(1):144. doi: 10.1186/s12933-019-0949-3.
Results Reference
derived
PubMed Identifier
28202051
Citation
Carpeggiani C, Picano E, Brambilla M, Michelassi C, Knuuti J, Kauffman P, Underwood SR, Neglia D; EVINCI Study Investigators. Variability of radiation doses of cardiac diagnostic imaging tests: the RADIO-EVINCI study (RADIationdOse subproject of the EVINCI study). BMC Cardiovasc Disord. 2017 Feb 16;17(1):63. doi: 10.1186/s12872-017-0474-9.
Results Reference
derived
PubMed Identifier
25711274
Citation
Neglia D, Rovai D, Caselli C, Pietila M, Teresinska A, Aguade-Bruix S, Pizzi MN, Todiere G, Gimelli A, Schroeder S, Drosch T, Poddighe R, Casolo G, Anagnostopoulos C, Pugliese F, Rouzet F, Le Guludec D, Cappelli F, Valente S, Gensini GF, Zawaideh C, Capitanio S, Sambuceti G, Marsico F, Perrone Filardi P, Fernandez-Golfin C, Rincon LM, Graner FP, de Graaf MA, Fiechter M, Stehli J, Gaemperli O, Reyes E, Nkomo S, Maki M, Lorenzoni V, Turchetti G, Carpeggiani C, Marinelli M, Puzzuoli S, Mangione M, Marcheschi P, Mariani F, Giannessi D, Nekolla S, Lombardi M, Sicari R, Scholte AJ, Zamorano JL, Kaufmann PA, Underwood SR, Knuuti J; EVINCI Study Investigators. Detection of significant coronary artery disease by noninvasive anatomical and functional imaging. Circ Cardiovasc Imaging. 2015 Mar;8(3):e002179. doi: 10.1161/CIRCIMAGING.114.002179.
Results Reference
derived
Links:
URL
http://www.escardio.org/communities/EACVI/studies-registries/EVINCI/Pages/EVINCI-home.aspx
Description
Related Info

Learn more about this trial

Evaluation of Integrated Cardiac Imaging in Ischemic Heart Disease

We'll reach out to this number within 24 hrs